News

Summit said to be in talks with Astra to license potential rival for Merck’s Keytruda
Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, ...
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts.
Zacks Investment Research on MSN4d
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade
Shares of Summit Therapeutics PLC (SMMT) have gained 2.8% over the past four weeks to close the last trading session at $21.2 ...
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential
Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...
Tesla's UK sales jump in June from a year earlier, data shows
Tesla's new car sales in Britain rose year-on-year in June amid a broader recovery in the electric-vehicle market, data ...
Nasdaq2d
Noteworthy Thursday Option Activity: ITT, SMMT, DIS | Nasdaq
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ITT Inc (Symbol: ITT), where a total of 2,245 contracts have traded so far ...